Clinical Trial Results TV
March 14, 2010: Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiov
At ACC 2010, Dr. Henry Ginsberg presents: Effects of Combination Lipid Therapy on
Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Lipid Trial.

Dr. Ginsberg reports receiving:

- Consulting fees from Merck, Merck Schering Plough, Bristol-Myers Squibb, AstraZeneca,
Abbott, Roche, Isis/Genzyme, GlaxoSmithKline, Novartis, Pfizer, and Regeneron/
SanofiAventis.

- Grant support from Merck, ISIS/Genzyme, Roche, and AstraZeneca.

[ Download video ]


Video Statistics
5 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 1 total votes.

These statistics are updated nightly. The last update ran on
10-19-2018 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted